# Glossary of Peptide & Clinical Terms: A Reader's Reference

> A source-cited definitional reference to the vocabulary of peptide, hormone, and longevity science — from receptor pharmacology and pharmacokinetics to manufacturing quality and the U.S. and anti-doping regulatory landscape.

*Published 2026-07-01 · Updated 2026-07-01 · By The PeptideVox Editorial Desk*

The short answer
Peptide, hormone, and longevity content is dense with jargon that hides real distinctions — between a peptide and a protein, between an activator and a blocker, between an FDA-approved drug and a chemical labeled "research use only." This glossary defines those terms in plain language, each grounded in a primary FDA, WADA, USP, or peer-reviewed source, so you can read a monograph and know exactly what is being claimed and how strong the evidence behind it is.[1](https://peptidevox.com/#r1)[27](https://peptidevox.com/#r27)

Across this site, efficacy statements carry an **evidence grade** so you can separate *proven in humans* from *promising in a petri dish* from *marketing*. This reference collects the vocabulary those grades and monographs rely on. It is **informational and educational content, not medical advice**, not a prescription or protocol, and **not a sourcing or buying guide**. Many peptides discussed in this field are not FDA-approved, are sold as research chemicals "not for human consumption," and/or are prohibited in sport. Where dosing or routes are mentioned, they are reported as described in the published literature for definitional completeness only.

## What is a peptide, and how is it different from a protein?

A **peptide** is a short chain of **amino acids** — the monomer building blocks joined head-to-tail by **peptide bonds** (the covalent amide linkage between one amino acid's carboxyl group and the next one's amino group). A single amino-acid unit within an assembled chain is a **residue**, which is how chain length is counted. Because there is no universal scientific cutoff, the U.S. FDA adopted a regulatory threshold: any alpha-amino-acid polymer of **40 residues or fewer** is treated as a peptide (regulated as a **drug**), and anything **greater than 40** is a **protein**, regulated as a **biologic**.[1](https://peptidevox.com/#r1) You can read the FDA's own reasoning in the 2018 [Federal Register definition of a biological product](https://www.federalregister.gov/documents/2018/12/12/2018-26840/definition-of-the-term-biological-product), which notes that, other than size, no precise structural attribute cleanly separates the two.[1](https://peptidevox.com/#r1)

On this basis semaglutide (31 amino acids), leuprolide (9), and octreotide (8) are peptide *drugs*, while even insulin (51 amino acids) was reclassified as a biologic in 2020.[2](https://peptidevox.com/#r2) A **small molecule**, by contrast, is a low-molecular-weight (typically under 1,000 Da) chemically synthesized drug; peptides occupy a middle ground between small molecules and larger biologics.[2](https://peptidevox.com/#r2) An **analog** is a molecule structurally modified from a parent compound to change its properties — GLP-1 analogs such as liraglutide and semaglutide are nearly identical to native GLP-1 but engineered to extend half-life.[13](https://peptidevox.com/#r13) **Endogenous** substances are made inside the body (ghrelin, GLP-1, IGF-1); **exogenous** ones are introduced from outside; and **recombinant** molecules are produced by genetically engineered cells rather than by synthesis or extraction.[11](https://peptidevox.com/#r11)

## How do peptides act on receptors, and what do the pharmacology terms mean?

A **receptor** is a protein — often on the cell surface — that a signaling molecule (a **ligand**) binds to, triggering a biological response. Many peptide hormones act on **G-protein-coupled receptors (GPCRs)**, seven-transmembrane proteins that convert an outside binding event into an inside signal.[8](https://peptidevox.com/#r8) How a ligand behaves once bound is the crux of pharmacology.

  Core receptor-pharmacology terms

    TermWhat it means

    AgonistBinds and activates the receptor, producing a response; a full agonist gives the maximal effect
    Partial agonistBinds and activates but only submaximally; can blunt a full agonist by competing for the site
    AntagonistBinds but does not activate, blocking an agonist from acting; has no intrinsic activity
    Inverse agonistDrives the opposite effect, lowering a receptor's baseline activity below its unliganded level
    Affinity (Kd)How tightly a ligand binds; a lower Kd means higher affinity
    Potency (EC50)The amount needed to produce a given effect; a lower EC50 means greater potency
    Efficacy (Emax)The maximum effect a drug can produce, regardless of dose

These distinctions come from standard pharmacology teaching: agonists, partial agonists, and antagonists differ in **intrinsic activity**, while affinity, potency, and efficacy are measured separately — two drugs can be equally efficacious yet differ in potency.[5](https://peptidevox.com/#r5)[6](https://peptidevox.com/#r6) A drug's safety margin is its **therapeutic index** (roughly the toxic dose over the effective dose), and dosing aims to keep concentrations inside the **therapeutic window**.[6](https://peptidevox.com/#r6) Continued stimulation can blunt a receptor: **desensitization** is a rapid drop in responsiveness (via receptor phosphorylation, beta-arrestin binding, and internalization), **downregulation** is an actual reduction in receptor number, **tachyphylaxis** is rapid loss of response after repeated dosing, and **tolerance** is the slower, days-to-weeks version — the reason some peptide protocols cycle or pulse dosing.[7](https://peptidevox.com/#r7)

## What are the growth-hormone and metabolic peptide terms?

The growth-hormone axis is a common source of confusion. **Growth hormone (GH)** is released from the pituitary under two opposing hypothalamic signals: **GHRH** (stimulatory) and somatostatin (inhibitory).[8](https://peptidevox.com/#r8) A **secretagogue** is anything that induces secretion of another substance; a growth hormone secretagogue is the umbrella term for compounds that raise GH, including GHRH-receptor agonists (sermorelin, CJC-1295, tesamorelin), ghrelin-receptor agonists (the GHRPs, hexarelin, ipamorelin), and the oral non-peptide ibutamoren.[9](https://peptidevox.com/#r9) The **GHSR (ghrelin receptor)** is the GPCR whose natural ligand is **ghrelin**, the "hunger hormone"; in healthy men GHRP-2, like ghrelin, increases both GH and food intake.[10](https://peptidevox.com/#r10) **IGF-1**, a 70-amino-acid peptide, is the principal downstream mediator of GH: GH stimulates the liver to make IGF-1, which drives anabolic and growth effects — the classic GH-IGF-1 axis.[11](https://peptidevox.com/#r11)

On the metabolic side, **GLP-1** is an **incretin** gut hormone released after eating that boosts glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite; its native half-life is under 1.5 minutes because the enzyme **DPP-4** rapidly degrades it.[14](https://peptidevox.com/#r14) A **GLP-1 receptor agonist** (incretin mimetic) is engineered to resist DPP-4 and extend dosing to daily or weekly — the class behind semaglutide and the dual GIP/GLP-1 agonist tirzepatide, whose weight-loss and cardiovascular benefits are Grade A from large human trials.[13](https://peptidevox.com/#r13) In the extracellular-matrix world, a **matrikine** (or matricryptin) is a peptide fragment liberated from the matrix that regulates cell activity; the copper tripeptide **GHK-Cu** is a canonical example whose wound-healing evidence remains largely preclinical (Grade C).[12](https://peptidevox.com/#r12)

## What do the pharmacokinetic and dosing abbreviations mean?

**Pharmacokinetics (PK)** is what the body does to a drug, summarized by **ADME**: absorption, distribution, metabolism, excretion.[3](https://peptidevox.com/#r3) **Pharmacodynamics (PD)** is the reverse — what the drug does to the body. The numbers you see in monographs come from PK: **half-life (t½)** is the time for a plasma concentration to fall by half and sets dosing frequency; **Cmax** is the peak concentration and **Tmax** the time it is reached; **AUC** (area under the curve) captures total exposure; and **bioavailability (%F)** is the fraction reaching circulation intact and active.[3](https://peptidevox.com/#r3) Intravenous delivery is 100 percent bioavailable by definition, but because of the **first-pass effect** — loss to liver and gut metabolism before reaching circulation — oral peptide bioavailability is typically under 1 to 5 percent, which is why **subcutaneous** injection is the dominant route.[4](https://peptidevox.com/#r4)[15](https://peptidevox.com/#r15) A **depot effect** is slow, sustained release from an injection site or an albumin-binding analog, allowing less frequent dosing.[13](https://peptidevox.com/#r13)

## What do the manufacturing, quality, and legal terms mean?

Most research and therapeutic peptides are shipped **lyophilized** (freeze-dried) — frozen, then dried under vacuum to a stable "cake" that resists hydrolysis — and must be **reconstituted** with a diluent before use, gently, to protect the peptide.[16](https://peptidevox.com/#r16) The diluent is often **bacteriostatic water** (containing 0.9 percent benzyl alcohol, which inhibits bacterial growth and permits multi-dose vials) or preservative-free **sterile water** for single use.[17](https://peptidevox.com/#r17) Quality is documented on a **Certificate of Analysis (COA)** — batch-specific identity, purity, potency, and sterility data — and governed by **USP** monographs and **cGMP**, the FDA-enforced current Good Manufacturing Practice regulations under 21 CFR 210-211.[18](https://peptidevox.com/#r18)[19](https://peptidevox.com/#r19) The active substance itself is the **API**, which must be made in compliance with cGMP under ICH Q7 expectations.[20](https://peptidevox.com/#r20) A product labeled **"research use only"** is a laboratory reagent — not made to pharmaceutical cGMP, not tested for human use, and carrying no FDA approval; the label does not make a product legal or safe to take.[21](https://peptidevox.com/#r21)

Legally, a peptide may be an FDA-approved drug, a **compounded** preparation, or an unapproved research chemical. The Drug Quality and Security Act created two compounding tracks: **503A** traditional pharmacies (patient-specific, state-overseen, exempt from full cGMP) and **503B** outsourcing facilities (FDA-registered, large batches allowed, full cGMP, direct inspection).[22](https://peptidevox.com/#r22) To compound from a bulk substance under 503A, that substance must clear the FDA's evaluation — the interim policy sorts nominees into **Category 1** (usable while under review) and **Category 2** (significant safety concerns, may not be used).[23](https://peptidevox.com/#r23) In late 2023 the FDA moved roughly 19 peptides, including BPC-157 and TB-500, to Category 2; some were later removed as nominations were withdrawn — but removal from Category 2 does not equal approval or Category 1 status.[24](https://peptidevox.com/#r24)[25](https://peptidevox.com/#r25)

Finally, sport has its own rules. The **WADA** Prohibited List places most peptide hormones in **category S2** — banned in and out of competition — with an "and related substances" clause broad enough to catch novel analogs.[27](https://peptidevox.com/#r27) Use is permitted only through a rarely granted **Therapeutic Use Exemption (TUE)**, and under **strict liability** an athlete is responsible for anything found in their sample regardless of how it arrived.[26](https://peptidevox.com/#r26)[28](https://peptidevox.com/#r28)

**Bottom line.** The vocabulary of this field encodes real, load-bearing distinctions — a 40-amino-acid legal line, an agonist versus a blocker, a validated cGMP API versus a research-chemical vial, an FDA-approved drug versus a Category-2 bulk substance, an S2-prohibited hormone versus a permitted one. Knowing the words is the first step to reading the evidence honestly. Regulatory facts here are current as of June 2026 and should be re-verified, because they change.

---
Source: https://peptidevox.com/guides-and-101/glossary-of-peptide-and-clinical-terms
Index: https://peptidevox.com/llms.txt · Full text: https://peptidevox.com/llms-full.txt